Compare Campbell Soup Co. (CPB) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Novartis AG — how do they compare? Campbell Soup Co. trades at $22.16 (market cap $6.59B), while Novartis AG trades at $150.12 (market cap $288.65B). The key difference: Novartis AG is far larger — about 43.8× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (7.06%). Which is the better fit depends on your goals.
| CPB | NVS | |
|---|---|---|
Market Cap | $6.59B | $288.65B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $168.62 |
52-Week Low | $20.00 | $113.50 |
Enterprise Value | $13.20B | $328.67B |
Dividend Yield | 7.06% | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.15, up 0.36% with neutral technical signals. The stock shows modest valuation metrics with P/E of 10.85 and P/S of 0.67, while recent earnings show mixed results with Q1 2026 beating expectations. Revenue growth remains stable at $10.25B for 2025, though profit margins have compressed from historical levels. The company maintains strong cash flow generation and recently launched new product innovations including protein soups and gluten-free options.
CPB offers value investors an attractive 7% dividend yield and reasonable valuation, but faces margin pressure and competitive headwinds. Analyst consensus leans cautious with 58.6% hold ratings, though recent product launches and cost initiatives provide potential catalysts. Key risks include ongoing margin compression and consumer spending sensitivity in the current economic environment.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
